gsk3228836
Nucleic acidexperimental
Clinical trial activity
16 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
12
Phase 3
2
Phase 4
0
Earliest trial started Feb 22, 2017 (NCT02981602)
Timeline
Indications
Mechanism of action
- mRNAANTISENSE INHIBITOR
mRNA antisense inhibitor
- Hepatitis B virusINHIBITOR
Hepatitis B virus inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650468 ↗
Also known as
- ionis-hbvrx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07168356 | Phase 1 | Sep 16, 2025 | GlaxoSmithKline |
| NCT06537414 | Phase 2 | Nov 25, 2024 | GlaxoSmithKline |
| NCT06497504 | Phase 2 | Sep 17, 2024 | GlaxoSmithKline |
| NCT06422767 | Phase 1 | Aug 14, 2024 | GlaxoSmithKline, PPD |
| NCT06058390 | Phase 1 | Sep 26, 2023 | GlaxoSmithKline |
| NCT05630807 | Phase 3 | Dec 8, 2022 | GlaxoSmithKline |
| NCT05630820 | Phase 3 | Nov 30, 2022 | GlaxoSmithKline |
| NCT05561673 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2022 | GlaxoSmithKline |
| NCT05330455 | Phase 1/Phase 2 (Phase 2) | Apr 14, 2022 | GlaxoSmithKline |
| NCT05276297 | Phase 2 | Mar 22, 2022 | GlaxoSmithKline |
| NCT04954859 | Phase 2 | Nov 30, 2021 | GlaxoSmithKline |
| NCT04971928 | Phase 1 | Sep 7, 2021 | GlaxoSmithKline |
| NCT04676724 | Phase 2 | Jan 28, 2021 | GlaxoSmithKline |
| NCT04544956 | Phase 2 | Oct 6, 2020 | GlaxoSmithKline |
| NCT04449029 | Phase 2 | Jul 27, 2020 | GlaxoSmithKline |
| NCT02981602 | Phase 2 | Feb 22, 2017 | Ionis Pharmaceuticals, Inc., PPD |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 15 | 15 | 3 | 2020 |
| PPD | For profit | 2 | 0 | 2 | 2017 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2017 |
3 organizations
Page 1 / 1